Challenges and Perspectives in Subgroup Analyses for Regulatory and HTA Methods
This presentation discusses the importance of subgroup analyses in pharmaceutical development, focusing on perspectives from regulatory agencies, HTA bodies, and the pharmaceutical industry. It highlights the challenges, methods, and recommendations for optimizing subgroup analyses to enhance drug d
0 views • 26 slides
Enhancing Government Decision-Making with Health Technology Assessment in South Africa
Health Technology Assessment (HTA) plays a crucial role in informing policy and funding decisions in South Africa, particularly in the context of the National Health Insurance (NHI) aiming for universal healthcare coverage. This multidisciplinary process assesses the value and impact of health techn
0 views • 17 slides
Understanding the Human Tissue Act 2004 and DNA Analysis
The Human Tissue Act 2004 regulates the removal, storage, and use of tissue and organs from both living and deceased individuals in England, Wales, and Northern Ireland. The Human Tissue Authority (HTA) oversees the implementation of this act, ensuring safe and ethical use of human tissue. Consent i
0 views • 20 slides
EU Health Technology Assessment Initiative Overview
The EUnetHTA assembly in May 2018 discussed the background, key milestones, objectives, outcomes, and proposal of the Health Technology Assessment (HTA) initiative. The initiative aims to promote convergence in HTA tools, reduce duplication of efforts, ensure sustainability, and bring positive impac
0 views • 21 slides
Evidence-Based Decision Making for Health Technology Implementation
The implementation of new technologies in healthcare must be evidence-based and cost-effective. Health Technology Assessment (HTA) plays a crucial role in evaluating the effectiveness, cost, and comparative benefits of various health technologies. Organizations like NICE provide guidance based on cl
0 views • 17 slides
Understanding Adjusting Effects for Treatment Switching in Health Technology Assessment (HTA)
Treatment switching in HTA refers to patients changing from one treatment to another during a clinical trial. It can impact the comparison of existing treatments to new therapies in HTA evaluations. Different methods are used to estimate survival rates in control groups without considering treatment
0 views • 20 slides
Regulation of Human Tissue and DNA Analysis under HTA 2004
The Human Tissue Act 2004 regulates the removal, storage, and use of tissues from deceased and living individuals. The Human Tissue Authority oversees the implementation of this act and provides guidance on safe and ethical use of human tissue. The act covers bodily and relevant material and emphasi
0 views • 20 slides